The European Lifestars Awards (ELAs) are an annual event that acknowledges and celebrates the significant achievements within the life sciences sector across Europe.
These awards recognise the innovation and ground-breaking achievements of the life sciences industry's most distinguished executive leaders, investors, partners, and dealmakers for their outstanding contributions to the advancement of the industry.
The "Biotech of the Year" award recognises a company that has shown outstanding excellence in strategy, process, focus and execution, and has created significant value for patients, investors, employees and the broader life science community.
"We are incredibly proud to receive the "Biotech of the Year" award, which signifies a landmark moment for Amolyt as we mark a pivotal year of growth,” said Thierry Abribat, PhD, founder and CEO of Amolyt Pharma.
“This accolade reflects the tireless dedication of our team, under the expert guidance from our board of directors, and with strong support from our investors."
"Together, we've cultivated a culture of excellence and commitment towards patients, advancing our clinical pipeline of therapeutic peptides for rare endocrine diseases."
"As we edge closer to potentially bringing eneboparatide to market for patients with hypoparathyroidism, this honor is a tribute to the collective efforts and unwavering spirit of our employees since the company's launch 4 years ago."
